New treatments to slow down Alzheimer's disease
Official title: Novel Disease-modifying Small Molecules for Treatment of Alzheimer's Disease”
Funded at Minneapolis VA Medical Center · NIH-11013850 · Data updated 2026-11-12
This study is looking at new ways to help people with Alzheimer's by targeting a protein that may be causing memory problems, with the hope of improving thinking skills and slowing down the disease.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Minneapolis VA Medical Center NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project start | January 1, 2023 |
| Project end | December 31, 2026 |
| Funding year | 2025 |
| NIH project number | 5I01BX005934-03 |
| Project ID | NIH-11013850 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Alzheimer's disease, particularly those with genetic factors such as APOE4 that may influence disease progression.
✕Less likely to help
Patients with other forms of dementia or those without a diagnosis of Alzheimer's disease may not benefit from this research.
What this research studies
This research focuses on developing new small molecules that target a protein called synaptojanin 1, which is linked to cognitive decline in Alzheimer's disease. By reducing the levels of this protein, the study aims to improve cognitive function and slow the progression of neurodegeneration associated with Alzheimer's. The approach involves understanding how synj1 affects brain health and exploring its potential as a therapeutic target. Patients may benefit from innovative treatments that could alter the course of their disease.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly slow the progression of Alzheimer's disease and improve cognitive function.
How similar studies have gone: Previous research has shown promising results in targeting synaptojanin 1 for cognitive improvement in Alzheimer's, indicating potential for success in this novel approach.
Where this research is happening
-
Minneapolis VA Medical Center
Minneapolis, United States Active
Researchers
- Principal investigator: Cai, Dongming — Minneapolis VA Medical Center
- Study coordinator: Cai, Dongming
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.